Cancer Therapy AdvisorBristol, AbbVie drug extends multiple myeloma remission: studyReutersThe addition of an experimental Bristol-Myers Squibb biotech medicine to standard therapy for patients whose multiple myeloma has relapsed led to longer remissions and cut the risk of death over standard treatment alone, according to data from a late stage ...Bristol and AbbVie's Experimental Drug Delayed Blood Cancer Progression ...Wall Street JournalASCO '15 -- Bristol, Abbvie Immune-Boosting Drug Lowers Progression Risk in ...TheStreet.comElotuzumab Combo Delays Myeloma Progression in Phase III TrialOncLiveCancer Networkall 6 news articles »
Bristol, AbbVie drug extends multiple myeloma remission: study
Rating: 4.5
Diposkan Oleh: Unknown
